Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a...

por Neal, Joel W., Dahlberg, Suzanne E., Wakelee, Heather A., Aisner, Seena C., Bowden, Michaela, Huang, Ying, Carbone, David P., Gerstner, Gregory J., Lerner, Rachel E., Rubin, Jerome L., Owonikoko, Taofeek K., Stella, Philip J., Steen, Preston D., Khalid, Ahmed Ali, Ramalingam, Suresh S.
Publicado 2016